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Introduction: Reduced glutathione and excess free iron within dopaminergic, substantia 
nigra neurons in Parkinson’s disease (PD) can drive accumulation of toxic hydroxyl radicals 
resulting in sustained oxidative stress and cellular damage. Factors such as brain penetrance 
and bioavailability have limited the advancement of potential antioxidant and iron chelator 
therapies for PD.  
Objective: This study aimed to develop novel nanocarrier delivery systems for the 
antioxidant curcumin and/or iron chelator deferoxamine (DFO) to protect against rotenone-
induced changes in cell viability and oxidative stress in SH-SY5Y cells.  
Method: Nanocarriers of curcumin and/or DFO were prepared using Pluronic F68 (P68) with 
or without dequilinium (DQA) by modified thin-film hydration. Cell viability was assessed 
using an MTT assay and oxidative stress was measured using Thiobarbituric acid reactive 
substances (TBARS) and cellular antioxidant activity (CAA) assays. 
Results: All formulations demonstrated high encapsulation efficiency (65-96%) and 
nanocarrier size was <200nm. 3h-pretreatment with P68 or P68+DQA nanocarriers 
containing various concentrations of curcumin and/or DFO significantly protected against 
rotenone-reduced cell viability. The addition of DFO to curcumin-loaded P68+DQA 
nanocarriers resulted in increased protection by at least 10%. All nanoformulations 
significantly protected against rotenone-induced lipid peroxidation (p < 0.0001). The 
addition of DQA, which targets mitochondria, resulted in up to 65% increase in cellular 
antioxidant activity. In nearly all preparations, the combination of 10uM curcumin and 
100uM DFO had the most antioxidant activity.  
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Conclusion: This study demonstrates for the first time the formulation and delivery using 
P68 and P68+DQA curcumin and/or DFO nanocarriers to protect against oxidative stress 
induced by a rotenone PD model. This strategy to combine antioxidants with iron chelators 
may provide a novel approach to fully utilise their therapeutic benefit for PD. 
1. Introduction  
Post mortem analysis and MRI techniques have highlighted a marked accumulation of free 
iron within the substantia nigra (SN) in Parkinson’s disease (PD) [1-6]. This, together with 
reduced levels of the natural antioxidant glutathione, can drive accumulation of toxic 
hydroxyl radicals within mitochondria resulting in sustained oxidative stress and 
catastrophic cellular damage [7, 8]. Iron-induced oxidative stress is likely a key contributor 
to the neurodegeneration observed in PD since intra-nigral injection of iron in rats induces 
both a PD-like phenotype and pathology [9]. Elevated iron deposition in the SN of people 
with PD have been significantly correlated with motor symptoms and some non-motor 
symptoms such as cognitive, sleep and autonomic issues [10].  
Iron chelators and antioxidants therefore hold promise as potential neuroprotective 
therapies for PD. Ward et al [11] were the first group to demonstrate that bidentate iron 
chelators like deferiprone (DFP) and deferoxamine (DFO) were able to remove excess brain 
iron in animal models of brain iron overload. Iron chelators have since been demonstrated 
to be neuroprotective in 6-hydroxydopamine (6-OHDA) animal models of PD [12, 13]. 
Furthermore, a recent clinical trial of the iron chelator DFP correlated chelator use with a 
decrease in the UPDRS score for motor symptoms [14]. Similarly, in both in vitro and in vivo 
PD models, curcumin has been able to protect against dopaminergic neurodegeneration. 
For example, in a cellular rotenone-induced neurotoxin model of PD curcumin reduced 
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reactive oxygen species (ROS) and cytotoxicity as well as inhibited caspase 3 and 9 
activation, preventing apoptosis [15]. Likewise, in a mutant A53T α-synuclein (α-syn) cellular 
model of PD curcumin pre-treatment reduced cell death as well as levels of mutant a-syn 
[16] and in an in vivo drosophila model of PD curcumin not only reduced cell death but also 
ameliorated PD-like symptoms [15]. More recent evidence suggests that curcumin is also 
protective against mitochondrial dysfunction. Van der Merwe et al [17] showed curcumin to 
be protective in a PINK1 knock down model of PD and PINK1 has an intrinsic role in the 
removal of dysfunctional mitochondria with mutations in PINK1 resulting in an early-onset 
autosomal recessive PD. The combination of iron chelators and antioxidant molecules may 
present a promising potential therapeutic approach for PD as together they are able to 
completely restore brain function impaired by iron overload in animal models [18].  
The free radical scavenging properties of curcumin and the potential of iron chelators such 
as DFO to limit the availability of detrimental free iron may be a promising mechanism to 
limit the degenerative process in PD. That said, the therapeutic value of these two 
compounds is limited as curcumin is unstable with low bioavailability and both are unlikely 
to access the brain at therapeutic concentrations [19, 20]. Furthermore, long-term effects of 
continuous iron chelator use are unknown in PD and due to the non-specific nature of such 
chelators the side effects could be serious since iron is an essential part of numerous cellular 
processes such as respiration [21] and neurotransmitter synthesis [22, 23].   
Nanocarriers have demonstrated potential as targeted delivery systems to improve stability 
of labile molecules and enhance delivery across membranes, including the blood-brain 
barrier (BBB), whilst retaining the potency of entrapped molecules [24, 25]. For example, 
studies which have altered the formulation of curcumin such as encapsulation in glycerol 
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monooleate have increased the half-life of curcumin [26]. Other nanoformulations of 
curcumin such as the poly(lactic-co-glycolic acid) (PLGA) nanoformulation have 
demonstrated BBB penetration and the ability to and enter brain tissues including the 
cerebral cortex and the hippocampus however, they are also found in other organs such as 
the spleen and the liver [27]. Zupančič et al [25] developed a DQAsome nanoformulation of 
curcumin using vesicles formed from the amphiphile dequalinium (DQA) which were able to 
specifically target mitochondria. Mitochondrial targeting of antioxidants in PD would be 
highly beneficial since mitochondria are the main site of intracellular free radical formation 
[7, 8, 28]. However, such nanoformulations of curcumin were not developed to gain access 
into the brain or treat neurodegeneration and therefore need to be assessed in relevant 
models in order to evaluate the potential benefit for PD. Therefore, this study aimed to 
develop nanocarrier, nasal delivery systems for curcumin and/or DFO using the amphiphilic 
polymer, Pluronic F68 (P68), with or without DQA to protect against rotenone-induced 
changes in cell viability and oxidative stress in SH-SY5Y neuronal cells. 
2. Materials and Methods  
2.1. Materials  
Unless otherwise stated, all chemicals were analytical grade. Dequalinium chloride hydrate 
(DQA; 95%), Dulbecco’s phosphate buffered saline (PBS), Curcumin from Curcuma longa 
(Turmeric), powder (≥80%), Deferoxamine mesylate salt (92.5%), Protease inhibitor cocktail 
(PIC), Thiazolyl Blue Tetrazolium Blue (MTT), Dimethyl sulfoxide (DMSO), 2′,7′-
Dichlorofluorescin diacetate (DCFH-DA) and 2,2′-Azobis(2-methylpropionamidine) 
dihydrochloride (ABAP) were purchased from Sigma-Aldrich, U.K. Methanol (HPLC grade), L-
glutamine, fetal bovine serum (FBS), Dulbecco’s Modified Eagle Medium (DMEM) 
 6 
 
Glutamax®, Minimum Essential Media (MEM) and 100×antibiotic-antimycotic were supplied 
by Fisher Scientific, U.K. The TBARS Parameter Assay Kit was purchased from R&D Systems, 
Parameter TM, UK. The BCA protein assay kit was from Pierce (Thermo Fisher Scientific, UK). 
SH-SY5Y cells were purchased from the American Type Culture Collection (ATCC CRL-2266, 
USA). Flasks were from Nunc, Denmark and culture plates from Corning, UK. 
2.2. Development and characterisation of nanoformulations  
2.21. Preparation of Curcumin and/or deferoxamine nanoformulations 
All nanoformulations were prepared using a modified thin-film hydration method [25, 29]. 
Briefly, P68 nanocarriers with or without DQA, curcumin and/or deferoxamine (DFO) at 
different ratios (table I) were formulated using a rotary evaporator (Hei-VAP Advantage 
Rotary Evaporator, Heidolph, Germany) at 200 rpm and 80°C under vacuum, using methanol 
as the solvent. The resultant thin film was hydrated with 10ml of distilled water and mixed 
thoroughly at 80°C for 1-2 min and sonicated using a VWR Ultrasonic cleaner bath USC300T 
(VWR International Limited, U.K.) for a further 1 min until the film was fully removed and 
dissolved in the water. In order to remove any unloaded curcumin and/or DFO, the obtained 
formulation was filtered through a sterile 0.22μm filter (Millex-MP, Millipore, Carrigtwohill, 
Ireland). In order to store samples for further analysis, some samples were freeze dried 
(lyophilized) using a Virtis AdVantage 2.0 BenchTop freezedryer (SP Industries, UK).   
2.22.  Size and Surface Charge of the nanoformulations 
The size and surface charge of prepared nanoformulations were measured following 
filtration using the Zetasizer Nano ZS (Malvern Instruments, U.K.).  Size distribution was 
measured via photon correlation spectroscopy as Z-Ave hydrodynamic diameter and 
polydispersity index (PDI). Transmission electronmicroscopy (TEM) analysis was performed 
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to analyse morphology (size and shape) of the nanoformulation complexes. The surface 
charge was measured by laser Doppler micro-electrophoresis. All experiments were 
performed in triplicate.  
2.23. Determination of Drug Loading and Encapsulation Efficiency 
UV-Visible (UV-Vis) spectroscopy was employed to study drug loading and encapsulation 
efficiency of the nanoformulations based on the calibration curves of free curcumin and 
DFO. Methanol and water were added in a 1:1 ratio to dissolve the carrier in order to 
release the drug and achieve the theoretical concentration of 10μg/ml curcumin or 20μg/ml 
DFO. Curcumin and DFO content was calculated using UV-vis spectroscopy at 423 nm and 
204 nm respectively. The percentage of drug loading and encapsulation efficiency were 
calculated using the following equations:  
• Drug loading (%) = (determined mass of drug within nanocarriers / mass of drug-
loaded nanocarriers) X 100   
• Encapsulation efficiency (%) = (determined mass of drug within nanocarriers / 
theoretical mass of drug within nanocarriers) X 100 
 
2.3. Assessing the therapeutic potential of nanoformulations in a model of PD 
2.31. Cell culture and lysate harvesting 
The human neuroblastoma SH-SY5Y cell line was used to create and in vitro model of PD 
(reviewed in Xicoy et al. [30]). SH-SY5Y cells were grown in DMEM - Glutamax®, pH 7.4 
supplemented with 10% FBS and 1% antibiotic/antimycotic in a 5% CO2 environment at 
37°C. SH-SY5Y cells were thawed and left to grow in plastic T75 (75 cm2) flasks until they 
reached 70% confluence. Adherent cells were then detached from the surface of the flasks 
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via trypsinisation, counted and seeded into well plates at specific numbers according to the 
bioassay being performed (6-well or 96-well plates). To produce a model of PD, SH-SY5Y 
cells were treated with 100μM rotenone for 24h in order to reduce cell viability by 
approximately 50% (supplementary figure 1).  
2.32. Cell viability – MTT Assay   
The protective properties of drug-loaded nanocarriers against rotenone-induced reduction 
in cell viability was assessed using the MTT Assay. Briefly, SH-SY5Y cells grown at a seeding 
density of 1,000,000 cells/cm2 in 96 well plates until confluent. The cells were pre-treated 
for 3h with either free or nanoformulated curcumin (5 and 10 μM), DFO (100μM) or 
combined curcumin (5 or 10μM) and DFO (50 or 100μM), or with corresponding unloaded, 
blank formulations. SH-SY5Y cells were then treated with 100μM rotenone for 24h, each 
well containing a total volume of 200μl.  The cells were then incubated with an additional 
20μl of 5 mg/ml solution of MTT DPBS solution for 4h at 37°C. Following aspiration, 100μl of 
DMSO was added to each well to dissolve the formazan crystals. To ensure DMSO was 
mixed well, plates were placed on a shaker at 75rpm for 15 min and the absorbance was 
read at 570nm on a spectrophotometer.   
2.33. Lipid Peroxidation – TBARS assay  
The thiobarbituric acid-reactive-substances (TBARS) assay was used to assess ROS generated 
oxidative stress, specifically lipid peroxidation [31, 32].  Briefly, SH-SY5Y cells were grown in 
6-well plates until confluent. Following pre-treatment with the relevant free or 
nanoformulated curcumin and/or DFO, the cells were incubated with 100μM rotenone for 
24h. Cells were then washed once with DPBS and lysed at 4°C as previously described 
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by Zariwala et al [33], using 350 µl ice-cold lysis buffer (50mM NaOH supplemented with 
1μg/ml protease inhibitor cocktail - PIC) whilst rocking gently for 40 min in ice trays on a 
plate shaker (8 rpm). Cell lysates were then collected using sterile cell scrapers and 
aliquoted into microcentrifuge tubes ready for further analysis. The lysate total protein 
concentrations were determined using the Pierce BCA kit with BSA as standard. The TBARS 
assay was carried out in accordance to manufacturer guidelines (R&D Systems, Parameter 
TM). Briefly, freshly prepared TBA was added to TBARS acid-treated cell lysate samples 
(loaded in triplicate) and incubated at 60 °C for 2.5h. The samples were read at absorbance 
532 nm before and after incubation to estimate the formation of TBARS.  
2.34. Cellular antioxidant activity – CAA Assay  
The cellular antioxidant activity was measured using the method described by Chen et al 
[34] which is a slightly modified version of the assay developed by Wolfe, et al [35] and Hu, 
et al [36]. SH-SY5Y cells were seeded in black-walled, clear-bottom 96-well 
microplates. Once confluent, cells were washed with DPBS and treated with different 
concentrations of 200μl of drug-loaded nanocarriers, free drug solution or MEM only 
(control) for 1-3 h at 37°C. Cells were then washed with MEM and treated with 200μl of 
100μM DCFH-DA (dissolved in MEM) and incubated for a further 30 min at 37 °C. Following 
aspiration, each well was treated with 100μl of 600μM ABAP (dissolved in MEM). The 
fluorescence of the cells in the 96-well plate was read every 5 minutes for 1h at 528 nm and 
485 nm emission and excitation wavelengths (respectively).   
2.35. Statistical Analysis.  
For all experiments the mean of six replicates was calculated for each treatment, and the 
data expressed as mean ± standard deviation (S.D.). The MTT and TBARS assay results were 
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statistically analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s T3 
post hoc test. A two-way ANOVA followed by Tukey’s multiple comparisons post hoc test 
was used to analyse the CAA assay results (PRISM software package, Version 7, Graphpad 
Software Inc., San Diego, USA). 
3. Results  
 All P68 nanoformulations demonstrated high encapsulation efficiency (66-95%), DFO-
loaded P68 nanocarriers had the highest mean encapsulation efficiency (95%), curcumin-
loaded nanocarriers had 79% and the combined curcumin (67%) and DFO (66%) 
nanocarriers had the lowest encapsulation efficiencies (table 1). The mean P68 nanocarrier 
size was <200 nm in all cases, however curcumin-loaded nanocarriers had the largest 
particle sizes (table 1). All P68 nanoformulations had low polydispersity as represented by 
mean polydispersity indices <0.22 suggesting that the majority of the nanocarriers within 
the formulation are of a similar size (table 1). All P68 nanocarriers had similar low negative 
surface charges (table 1). The addition of DQA to formulate the P68+DQA nanocarriers did 
not significantly change the particle size, however it did result in more positive surface 
charges (0.02 to 9.29) and in all cases appears to have increased encapsulation efficiency; 
curcumin-loaded nanocarrier encapsulation efficiency increased by 7%, DFO-loaded 
nanocarriers increased by 1% and combined curcumin and DFO-loaded nanocarriers had the 
largest increase of 10-20% for each drug, from 67% and 66% to 82% and 96%, respectively 
(table 1). 
24h treatment with 100μM rotenone significantly reduced SH-SY5Y cell viability by 40-50% 
in all experiments (figure 2A, B, supplementary figure 1).  Cytotoxicity was not observed for 
the tested concentrations of any nanoformulation ≥80% (n=6). When comparing the effects 
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of free drug and P68 nanocarriers on cell viability following rotenone treatment, a 
significant difference in mean cell viability was observed between the different treatments 
(F(16, 94)= 93.97, p < 0.0001) (figure 2A).  3-hour pre-treatment of P68 nanocarriers of 5μM 
and 10μM curcumin (p = 0.0039 and p = 0.0078, respectively), 100μM DFO (p = 0.0002) and 
combined 5μM curcumin and 50μM DFO (p = 0.0029) significantly protected against the 
reduction in cell viability induced by 24h treatment with 100μM rotenone (figure 2A). Of the 
P68 nanoformulation conditions which were protective, no single condition was significantly 
more protective than another. None of the free drug pre-treatment conditions apart from 
combined 5μM curcumin and 50μM DFO (p = 0.0219) were able to significantly protect 
against rotenone and pre-treatment with the combination of free curcumin (10μM) and free 
DFO (100μM) followed by rotenone treatment appears to be more toxic than rotenone 
alone (p = 0.0003) (figure 2A).  There was no significant difference in cell viability following 
pre-treatment with P68 nanocarriers compared to the corresponding free drug pre-
treatments apart from with 10μM curcumin + 100μM DFO where pre-treatment with P68 
nanocarriers resulted in higher cell viability (p = 0.0032). 
Similarly, there was a significant difference in mean cell viability between the different 
treatments when comparing free drug and P68+DQA nanocarrier pre-treatments prior to 
rotenone treatment (F(16, 60) = 5.639, p < 0.0001) (figure 2B). The majority of P68+DQA 
nanoformulation pre-treatments were able to protect against rotenone, (5μM curcumin (p < 
0.0001), 10μM curcumin (p = 0.0331), 5μM curcumin + 50μM DFO (p = 0.0104), 10μM 
curcumin + 100μM DFO (p = 0.014)), including the combination for 10μM curcumin and 
100μM DFO which was not protective in the P68 or free conditions (figure 2B). However, 
P68+DQA nanocarriers of 100μM DFO did not significantly protect against rotenone. In 
these results, free 5μM curcumin pre-treatment was also able to significantly protect 
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against rotenone (p = 0.0455). Similar to when using P68 nanocarriers, when comparing 
P68+DQA nanocarriers with the corresponding free drug pre-treatments, there was only a 
significant difference found for 10μM curcumin + 100μM DFO where pre-treatment with 
P68+DQA nanocarriers resulted in higher cell viability (p = 0.004).  
A significant difference in mean TBARS concentrations was observed between the different 
treatments when testing both P68 (F(16, 84) = 35.36, p < 0.0001) and P68+DQA (F(16, 17) = 
41.55, p < 0.0001) nanocarriers compared to the corresponding free drugs (figure 3A, B). 3-
hour pre-treatment of all preparations (free drug, P68 and P68+DQA nanoformulations) of 
all conditions (5μM curcumin, 10μM curcumin, 100μM DFO, 5μM curcumin + 50μM DFO, 
10μM curcumin + 100μM DFO) significantly protected against rotenone-induced lipid 
peroxidation, measured by TBARS concentration (figure 3A, 4B). 3-hour pre-treatment with 
P68 nanocarriers of 5μM and 10μM curcumin (p = 0.0012 and p = 0.0135, respectively), 
100μM DFO (p = 0.0012) and the combination of 5μM curcumin and 50μM DFO (p = 0.0007) 
were significantly more protective against rotenone-induced increase in TBARS 
concentration compared to the corresponding free drug conditions (figure 3A). There was 
no significant difference in the ability of P68+DQA nanocarriers and the corresponding free 
drug pre-treatments to protect against rotenone-induced lipid peroxidation (figure 3B).  
The CAA results showed significant differences in cellular antioxidant activity between the 
different treatment preparation types (F(4, 100) = 27.78, p < 0.0001) and the different 
concentrations of treatments (F(3, 100) = 26.78, p = p < 0.0001) (figure 4A, B). P68+DQA 
drug loaded nanocarriers had significantly higher antioxidant capability than P68 
nanocarriers in all corresponding conditions except 100μM DFO where there was no 
significant difference (figure 4A). The highest difference in antioxidant activity between 
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these formulations was at 10μM curcumin concentrations, where P68+DQA curcumin-
loaded nanocarriers had 63% higher antioxidant activity compared to P68 curcumin-loaded 
nanocarriers (p < 0.0001) (figure 4A). Likewise, P68+DQA drug loaded nanocarriers had 
significantly higher cellular antioxidant activity compared to P68 drug loaded nanocarriers at 
5μM curcumin (48%, p = 0.001), 5μM curcumin + 50μM DFO (48%, p = 0.0012), 10μM 
curcumin + 100μM DFO (30%, p = 0.0063) concentrations. 100μM DFO P68+DQA 
nanocarriers also had higher antioxidant activity, 21% higher than P68 DFO-loaded 
nanocarriers at this concentration, although not significant (figure 4A).  P68+DQA 
nanocarriers were also significantly superior in cellular antioxidant activity compared to the 
corresponding curcumin free drug+DQA conditions (5μM and 10μM curcumin (p = 0.0003 
and p = 0.0022 respectively) (figure 4A). There was no significant difference in cellular 
antioxidant activity of P68+DQA nanocarriers compared to any of the corresponding free 
drug alone conditions. There was also no significant difference between P68 nanocarriers 
and free drug+DQA for any of the conditions apart from 10μM curcumin + 100μM DFO 
where free drug+DQA was superior (p = 0.0337) (figure 4A). However, in the majority of 
cases the free drug conditions had a significantly higher cellular antioxidant unit than the 
corresponding P68 nanocarriers (10μM curcumin (p = 0.0083), 100μM DFO (p =0.0343), 
combination of curcumin and DFO for both 5μM + 50μM (p = 0.0203) and 10μM + 100μM (p 
= 0.0082), respectively) (figure 4A). In all preparations, free drug, free drug+DQA, P68 and 
P68+DQA, the combination of 10μM curcumin and 100μM DFO had the most antioxidant 
potential compared to the majority of other conditions (figure 4B).                                                                                                                                                                                                               
4. Discussion  
 14 
 
There is much evidence suggesting that curcumin and DFO are protective in numerous 
models of PD [12-17] and that the combination of such antioxidants and iron chelators may 
have even more potent effects [18]. However, the potential of these compounds as possible 
therapies for PD has been limited due to numerous factors such as brain penetrance, 
bioavailability and stability [19, 20]. Advances in nanotechnology have provided a possible 
solution to these issues as nanocarriers can be developed to retain the potency of the 
entrapped molecule while enhancing targeted delivery and passage across biological 
membranes [24, 25, 37, 38]. The aim of this study was to develop nanocarrier, nasal delivery 
systems for curcumin and DFO as well as the combination of the two and assess the ability 
of such nanocarriers to protect against reduced cell viability and increased oxidative stress 
in a cellular rotenone model of PD.  
Nanocarriers were developed using the amphiphilic polymer P68 as it has been successfully 
used to develop micellar nanocarriers of numerous compounds [39-41] including curcumin 
for other indications [42-45]. Mitochondrial targeting of nanocarriers using dequilinium has 
been established [25, 29, 46] therefore, the addition of dequilinium to the nanoformulation 
was used to assess whether mitochondrial targeting would result in increased potency. 
Curcumin and DFO were successfully incorporated into both P68 and P68+DQA nanocarriers 
(table 1). The mean size of both P68 and P68+DQA nanocarriers was fairly consistent, in 
both cases curcumin-loaded nanocarriers had a larger mean size than DFO-loaded 
nanocarriers, and the addition of DFO to curcumin further increased nanocarrier size but all 
were under 200nm. Such results are consistent with the ability to cross the BBB [37, 47].  
The mean surface charge of the P68 nanocarriers was relatively neutral, between -0.44 and -
5.88mV (table 1). This may also be beneficial for brain penetrance because most 
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nanocarriers with a low to moderate surface charge between -1mV and -15mV have been 
shown to pass the BBB [48-51]. The addition of DQA to the formulations resulted in a 
moderate increase in charge to a more positive state (+0.02 to +9.29mV), consistent with 
previous use of DQA in lipid-based formulations [25], however to a much lesser extent as 
such studies reported charges up to +50mV. This only slight – moderate increase in charge is 
more suitable for brain delivery as overall such charges are relatively neutral, not so positive 
to cause toxicity to the BBB, known to occur at high positive charges [52], but a large 
enough shift in charge to potentially improve physical stability [25]. Further to this, drugs 
are more likely to be able to pass the BBB if they are not rapidly cleared from the 
bloodstream [38] and neutral nanocarriers have been shown to have longer circulation time 
in the bloodstream compared to those that are very negatively or very positively charged 
[53]. 
P68 and P68+DQA nanocarriers were protective against rotenone-induced reductions in cell 
viability suggesting that they may be able to protect against cell death induced by rotenone. 
It was expected that the combination of the highest tolerable concentrations of curcumin 
and DFO would be the most effective at protecting against rotenone due to the combination 
of reduced free iron and increased antioxidants which together should prevent the 
accumulation of toxic free radicals which drive oxidative stress. However, pre-treatment 
with the combination of these free drugs appeared to result in toxicity following rotenone 
treatment (figure 2A, B). That said, following the combined formulation of 10μM curcumin 
and 100μM DFO into P68 and P68+DQA nanocarriers, pre-treatment with the combined 
drugs not only removed the toxicity previously observed but also significantly increased cell 
viability (figure 2A, B). P68 nanocarriers of 10μM curcumin and 5μM curcumin + 50μM DFO 
were the most successful at protecting cell viability against rotenone compared to the other 
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drug-loaded P68 nanocarriers, retaining cell viability over 80% (figure 2A). Whereas, 
increasing concentrations of P68+DQA curcumin and combined curcumin + DFO 
nanocarriers increasingly protected cell viability, with the pre-treatment of 10μM curcumin 
+ 100μM DFO retaining 90% cell viability (figure 2B). Although DFO-loaded P68+DQA 
nanocarriers did not significantly protect cell viability against rotenone, the addition of 
50μM and 100μM DFO to 5μM and 10μM curcumin-loaded P68+DQA nanocarriers resulted 
in a modest increase in protection, by 10% and 11% respectively. 
Similarly, all P68 and P68+DQA drug-loaded nanocarriers protected against rotenone-
induced lipid peroxidation, in all cases maintaining TBARS levels equivalent to control 
conditions (figure 3A, B). The results suggest that P68 but not P68+DQA drug-loaded 
nanocarriers are significantly more protective than the corresponding free drug pre-
treatments (figure 3A, B). However, it appears that the free drug preparation of all 
conditions resulted in lower TBARS concentrations in the experiment using the P68+DQA 
nanocarriers compared to when using P68 nanocarriers. This could be due to the cells 
having a higher starting TBARS concentration in the P68 experiment as measured by the 
control cells which did not receive any pre-treatment or rotenone treatment.   
The cellular antioxidant activity results suggest that P68+DQA drug-loaded nanocarriers of 
all conditions have more potent antioxidant potential than P68 drug-loaded nanocarriers. 
The addition of DQA to the formulations resulted in a significant increase from 48% to 65% 
in cellular antioxidant activity in all conditions apart from 100uM DFO where 20% higher 
antioxidant activity was observed but did not reach statistical significance (figure 4A). This 
suggests that the addition of DQA, which is known to target mitochrondria [25, 29, 46], 
significantly improves the antioxidant ability of the formulations. This result was anticipated 
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as mitochondria are the main site of intracellular free radical formation [7, 8, 28]. 
Furthermore, in nearly all preparations, the combination of 10μM curcumin and 100μM DFO 
had the most antioxidant activity (figure 4B), suggesting that the combination of increasing 
antioxidants and decreasing free iron may be the most successful strategy for reducing ROS 
production.  
Overall, these results suggest that all drug-loaded nanocarriers were at least as capable as 
the corresponding free drug conditions at protecting against reduced cell viability and 
increased lipid peroxidation induced by rotenone. As the potential therapeutic value of the 
free curcumin and DFO is limited due to issues such as bioavailability and brain penetrance 
[19, 20], the nanocarrier delivery systems may provide a viable solution as the particle size 
and charge data indicated that these formulations would be able to pass the BBB. 
Moreover, the ability to target these non-specific drugs to mitochrondria using P68+DQA 
nanocarriers seemed to result in increased cellular antioxidant activity. The outcome 
measures of these experiments focused mostly on antioxidant capability therefore it is 
unsurprising that the curcumin formulations were generally superior to DFO as curcumin is 
known to obtain antioxidant properties. However, for most preparations the addition of 
DFO to curcumin resulted in increased cellular antioxidant activity suggesting that a 
combination therapy may provide a good approach to combat oxidative stress in PD models. 
This is another benefit of using nanocarriers as, unlike combination delivery of free drugs 
which is challenging due to the distinct pharmacokinetic profiles of each drug, nanocarriers 
can ensure that drugs are delivered together for synergistic treatment [54]. 
In summary, this study demonstrates for the first time the formulation and delivery of P68 
and P68+DQA curcumin and/or DFO nanocarriers to protect against oxidative stress induced 
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by a cellular rotenone model of PD. This strategy may thus provide a novel approach to fully 
utilise their therapeutic benefit for PD. The next steps will be to assess additional 
parameters such as iron, dopamine and alpha synuclein prior to and following pre-
treatment with these formulations. As these results are from a neurotoxin model, in a 
neuroblastoma cell line that do not only contain dopaminergic neurons, further experiments 
will be carried out to determine if the effects are seen in more accurate models of PD, for 
example using patient derived induced pluripotent stem cells and in vivo alpha synuclein 
models. Such additional data would be valuable in providing the evidence needed as to 
whether these formulations can move forward into clinical testing as potential disease-
modifying therapies for PD.  
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Table 1. Hydrodynamic Diameter (d), Polydispersity Index (PDI), Surface Charge, Drug Loading (DL) and Encapsulation 
Efficiency (EE) of drug-loaded P68 and P68 + DQA nanoformulations prepared at 80°C (mean ± S.D. n=6) 
Sample  Contents  d (nm) PDI Charge (mV)  DL (%) EE (%) 
P68 - CU P68 10mg/ml 
CU  2mg/ml 
DFO  - 
 
184.3 ± 12.6 0.124 ± 0.040 -5.88 ± 5.74 13.49 ± 3.17 78.57 ± 21.26 
P68 - CU+ 
DFO  
P68 10mg/ml 
CU  0.28mg/ml 
DFO  5mg/ml 
 
177.2 ± 14.9 0.068 ± 0.029 -0.44 ± 2.72 CU: 1.40 ± 0.25  
DFO: 24.26 ± 
3.18 
CU: 66.91 ± 
10.40 
DFO: 65.63 ± 
11.10 
P68 - DFO P68 10mg/ml 
CU  - 
DFO  2mg/ml 
 




DQA  1mg/ml 
CU  2mg/ml 
DFO  - 
 
182.6 ± 31.5 0.099 ± 0.085 
 
4.27 ± 4.15 14.68 ± 1.55 86.17 ± 10.58 
P68+DQA - 
CU + DFO  
P68 9mg/ml 
DQA  1mg/ml 
CU  0.28mg/ml 
DFO  5mg/ml 
 
191.8 ± 45.3 0.078 ± 0.036 9.29 ± 5.12 CU: 1.01 ± 
0.19 
DFO: 31.77 ± 
1.80 
CU: 81.78 ± 
10.16 
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Figure 2. A. MTT assay results of 3-hour pre-treatment with free drug, P68 nanoformulated or corresponding blank 
preparations of either curcumin (C5, C10), deferoxamine (D100) or combined curcumin and deferoxamine (C5+D50, 
C10+D100) followed by 24-hour treatment with 100uM rotenone (R100) compared to R100 treatment alone. MEM 
represents the control condition where cells were only treated with media, no pre-treatment nor R100 treatment (n=6). B. 
Corresponding MTT assay results for P68+DQA nanoformulated pre-treatments (n=6). * represents significance values of 
control or pre-treatment conditions compared to R100 treatment alone (**** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * 
= p < 0.05). | represents significance values of nanoformulated drug compared to free drug within the same treatment 









Figure 3. A. TBARS assays results of 3-hour pre-treatment with free drug or P68 nanoformulated preparations of either 
curcumin (C5, C10), deferoxamine (D100) or combined curcumin and deferoxamine (C5+D50, C10+D100) followed by 24-
hour treatment with 100uM rotenone (R100) compared to R100 treatment alone. MEM represents the control condition 
where cells were only treated with media, no pre-treatment nor R100 treatment (n=6). B. Corresponding TBARS assay 
results for P68+DQA nanoformulated pre-treatments (n=6). * represents significance values of control or pre-treatment 
conditions compared to R100 treatment alone (**** = p < 0.0001, *** = p < 0.001, ** = p < 0.01). | represents significance 
values of nanoformulated drug compared to free drug within the same treatment condition (||| = p < 0.001, || = p < 0.01, | 




Figure 4. A. CAA assay results for free drug, free drug + DQA, P68 & P68 DQA preparations of curcumin (C5, C10), 
deferoxamine (D100) and combined curcumin and deferoxamine (C5+D50, C10+D100). * represent significance values 
within drug conditions (**** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * = p < 0.05). B. A table to show the corresponding 







Supplementary figure 1. MTT assay results of 24-hour 5uM – 100uM rotenone treatment. MEM represents the 
control condition where cells were only treated with media (n=6). * represents significance values of the 
treatment conditions compared to the control condition (**** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * = p < 0.05). 
